Idexx Laboratories, Inc.
IDXX
Market Cap$41.36B
Close$
Earnings Call Q4 2023
February 5, 2024 - AI Summary
IDEXX Laboratories reported strong fourth quarter and full year 2023 results, with revenues increasing by 8% organically in Q4 and 9% for the full year.
CAG Diagnostic recurring revenue grew by 10% organically in Q4, driven by gains in both the US (9%) and international regions (12%).
The company achieved solid organic growth across major testing modalities, with VetLab consumable revenues increasing by 13% organically in Q4.
Exclusive for Stockcircle Pro members
Sign up
$160.57
68.5% downside
Current Fair Value
68.5% downsideOvervalued by 68.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $41.36 Billion |
|---|---|
| Enterprise Value | $41.91 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $10.32 |
| Beta | 1.4 |
| Outstanding Shares | 82,587,328 |
| Avg 30 Day Volume | 518,380 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 47.73 |
|---|---|
| PEG | 474.65 |
| Price to Sales | 11.33 |
| Price to Book Ratio | 28.32 |
| Enterprise Value to Revenue | 11.25 |
| Enterprise Value to EBIT | 37.56 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.6 |
Revenue Sources
No data
ESG Score
No data
About Idexx Laboratories, Inc.
CEO: Jonathan Jay Mazelsky